Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the insider directly owned 103,221 shares in the company, valued at $12,831,402.51. The trade was a 2.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Johanna Mercier also recently made the following trade(s):

• On Monday, December 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00.
• On Monday, November 17th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00.

Gilead Sciences Stock Up 3.0%

Shares of Gilead Sciences stock traded up $3.65 during trading hours on Friday, reaching $124.91. The company’s stock had a trading volume of 10,638,850 shares, compared to its average volume of 6,570,563. The company has a market capitalization of $154.97 billion, a P/E ratio of 19.37, a P/E/G ratio of 0.65 and a beta of 0.33. The stock’s fifty day simple moving average is $123.24 and its two-hundred day simple moving average is $117.92. Gilead Sciences, Inc. has a one year low of $91.68 and a one year high of $128.70. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the business posted $2.02 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GILD. Rothschild & Co Redburn increased their price target on Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Sanford C. Bernstein set a $135.00 target price on shares of Gilead Sciences and gave the company an “outperform” rating in a report on Monday, December 29th. Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 3rd. Argus boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Royal Bank Of Canada decreased their price objective on shares of Gilead Sciences from $105.00 to $100.00 and set a “sector perform” rating for the company in a research note on Thursday, January 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $133.16.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GoalVest Advisory LLC increased its stake in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC bought a new position in Gilead Sciences during the third quarter valued at $26,000. Harbor Asset Planning Inc. bought a new position in Gilead Sciences during the second quarter valued at $27,000. Putney Financial Group LLC increased its position in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute purchased a new stake in Gilead Sciences in the second quarter worth $30,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.